STOCK TITAN
  1. Home
  2. News
  3. CERT

Certara to Participate in Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Certara, Inc. to participate in investor conferences
Positive
  • None.
Negative
  • None.

PRINCETON, N.J., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that Company management will participate in the following investor conferences:

  • Morgan Stanley 21st Annual Global Healthcare Conference 
    Date and Time: Tuesday, September 12 at 5:30 p.m. ET
  • Baird Global Healthcare Conference 
    Date and Time: Wednesday, September 13 at 3:45 p.m. ET

Live webcasts for each of the conferences will be available on Certara’s investor relations website at https://ir.certara.com and will be available for replay for at least 90 days thereafter.

About Certara
Certara accelerates medicines using proprietary biosimulation software, technology and services to transform traditional drug discovery and development. Its clients include more than 2,300 biopharmaceutical companies, academic institutions, and regulatory agencies across 70 countries.

Investor Relations Contact:
David Deuchler
Gilmartin Group
ir@certara.com

Media Contact:
Daniel Yunger
Kekst CNC
daniel.yunger@kekstcnc.com


Stock CERT logo
Certara, Inc.

NASDAQ:CERT

CERT Rankings

#1622 Ranked by Market Cap
#1974 Ranked by Stock Gains
N/A Ranked by Dividends

CERT Latest News

Apr 16, 2024
Certara Launches Cloud Platform to Further Unify its End-to-End Scientific Software Platform
Apr 9, 2024
Certara to Report First Quarter 2024 Financial Results on May 7th, 2024 and Participate in the BofA Securities Healthcare Conference
Feb 29, 2024
Certara Reports Fourth Quarter 2023 Financial Results
Feb 1, 2024
Certara to Report Fourth Quarter and Full Year 2023 Financial Results on February 29th, 2024 and Participate in the Barclays 26th Annual Global Healthcare Conference
Dec 13, 2023
Certara Acquires Applied BioMath Expanding Its Biosimulation Portfolio to Industrialize New Capabilities for Optimal Dosing for Novel Therapies

CERT Stock Data

2.82B
109.07M
2.92%
97.79%
3.55%
Software Publishers
Information
Link
United States of America
PRINCETON

About CERT

certara is a leading provider of decision support technology and consulting services for optimizing drug development and improving health outcomes. certara’s solutions, which span the drug development and patient care lifecycle, help increase the probability of regulatory and commercial success by using the most scientifically advanced modeling and simulation technologies and regulatory strategies. its clients include hundreds of global biopharmaceutical companies, leading academic institutions and key regulatory agencies. for more information, visit www.certara.com.